This webcast features: Chiu Lau-Barre, Application Staff Scientist,Thermo Fisher Scientific.

A record number of novel monoclonal antibodies (mAbs), bispecific antibodies (BsAb), and mAb fragments are entering clinical studies. Manufacturing of these new modalities requires a robust downstream purification process that produces high yield, purity, and productivity much like its mAb predecessor.

When the traditional platform purification of mAbs are applied to new engineered modalities, it can result in insufficient yields due to concentration of complex biproducts and poor binding of the target molecule to the protein A domain. Newer affinity chromatography resins have been developed specifically for the engineered modalities. They bind to different antibody-subdomain regions with high specificity and mild elution conditions to increase yield and reduce aggregation. These affinity resins can provide an improved solution for the purification of engineered novel mAbs, BsAb and mAb fragments.

Key Takeaways:

Register or Login and hit Watch on Demand to view the recorded webcast now.